Establishing cost-effectiveness of genetic targeting of cancer therapies

Valesca Retel; E.J.Th. Rutgers; M.A. Joore; Willem H. van Harten

Establishing cost-effectiveness of genetic targeting of cancer therapies

Valesca Retel, E.J.Th. Rutgers, M.A. Joore, Willem H. van Harten

Research output: Contribution to journal › Article › Academic › peer-review

2 Downloads (Pure)

Abstract

The clinical benefit of a new genomic instrument, the 70-gene signature for breast cancer patients, is being evaluated in a randomised clinical trial. The early, controlled implementation process is supported by a Constructive Technology Assessment to help decision-making in an uncertain time of development.

Original language	English
Pages (from-to)	28-31
Journal	European journal of oncology pharmacy
Volume	5
Issue number	1
Publication status	Published - 2011
Externally published	Yes

Access to Document

Retel2011establishingFinal published version, 249 KB

https://www.oalib.com/paper/2892037

Fingerprint Dive into the research topics of 'Establishing cost-effectiveness of genetic targeting of cancer therapies'. Together they form a unique fingerprint.

Cite this

@article{3732d6ac2fdf4eacb8c35cefc8e4f735,

title = "Establishing cost-effectiveness of genetic targeting of cancer therapies",

abstract = "The clinical benefit of a new genomic instrument, the 70-gene signature for breast cancer patients, is being evaluated in a randomised clinical trial. The early, controlled implementation process is supported by a Constructive Technology Assessment to help decision-making in an uncertain time of development.",

author = "Valesca Retel and E.J.Th. Rutgers and M.A. Joore and {van Harten}, {Willem H.}",

year = "2011",

language = "English",

volume = "5",

pages = "28--31",

journal = "European journal of oncology pharmacy",

issn = "1783-3914",

publisher = "Pharma Publishing and Media Europe",

number = "1",

}

TY - JOUR

T1 - Establishing cost-effectiveness of genetic targeting of cancer therapies

AU - Retel, Valesca

AU - Rutgers, E.J.Th.

AU - Joore, M.A.

AU - van Harten, Willem H.

PY - 2011

Y1 - 2011

N2 - The clinical benefit of a new genomic instrument, the 70-gene signature for breast cancer patients, is being evaluated in a randomised clinical trial. The early, controlled implementation process is supported by a Constructive Technology Assessment to help decision-making in an uncertain time of development.

AB - The clinical benefit of a new genomic instrument, the 70-gene signature for breast cancer patients, is being evaluated in a randomised clinical trial. The early, controlled implementation process is supported by a Constructive Technology Assessment to help decision-making in an uncertain time of development.

M3 - Article

VL - 5

SP - 28

EP - 31

JO - European journal of oncology pharmacy

JF - European journal of oncology pharmacy

SN - 1783-3914

IS - 1

ER -